Researchers at DTU have made a significant achievement by developing a new kind of electronic material that behaves almost exactly like human skin. That kind of substance could be useful in soft robotics, medicine, and healthcare.

Influenza continues to pose a significant global health burden, with seasonal outbreaks causing substantial morbidity and mortality. Current antiviral therapies, such as neuraminidase inhibitors and M2 inhibitors, face challenges like drug resistance and variable efficacy. ADC189, a novel cap-dependent endonuclease (CEN) inhibitor structurally related to baloxavir marboxil, emerges as a potential therapeutic candidate. This study evaluates ADC189’s preclinical antiviral activity, pharmacokinetics, and safety in a first-in-human phase I trial. Preclinical results demonstrate potent inhibition of influenza polymerase activity across multiple strains, including oseltamivir-resistant variants, and robust efficacy in murine models. Phase I data reveal favorable pharmacokinetic profiles, prolonged half-life, and no food-related absorption interference, supporting its development as a single-dose oral therapy for influenza.